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Cyclic vomiting syndrome (CVS) is a chronic functional gastrointestinal 
disorder with no certain treatment. We aimed to compare the efficacy of 
amitriptyline and topiramate on prophylactic therapy of CVS.
Materials and Methods
This randomized clinical trial (registration number: IRCT2015102316844N2) 
was conducted during 2016 in Isfahan, central Iran. The inclusion criteria 
were CVS patients (based on Rome III) aging 3-15 yr with normal 
physical examination, no metabolic disorder, and no gastrointestinal 
obstruction or renal impairment. Recruited patients were divided into two 
groups of amitriptyline (1 mg/kg/d) and topiramate (1-2 mg/kg/d) and 
were followed for 3-months. The outcome was evaluated by comparing 
severity of attacks (monthly frequency and duration of attacks) before 
and after intervention.
Results
Thirty-six children entered each group and two patients left the 
amitriptyline group. Patients and disease characteristics were similar 
between groups before intervention (P>0.05). The frequency of attacks 
(standard deviation) after intervention in amitriptyline and topiramate 
group was 0.91 (0.40) and 1.07 (0.55), respectively (P=0.368) and 
the duration of attacks (SD) after intervention were 3.43 (2.46) and 
4.90 (3.03), respectively (P=0.017). Twenty-three patients (68%) in 
amitriptyline group and 14 patients (39%) in topiramate group stopped 
having attacks after intervention (P=0.016).
Conclusion
Amitriptyline is a better choice to reduce severity of CVS attacks compared 
to topiramate, in a short-term evaluation. Studies with longer follow-up are 
required to investigate these findings in a longer period.
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(up to 6 times/h), and with debilitating nausea 
that can cause severe dehydration and may lead to 
intravenous therapy (1). Other symptoms include 
pallor, lethargy, nausea, abdominal pain, loss of 
appetite, photophobia and headache (1). CVS is 
usually misdiagnosed with other disorders since 
there are no specific symptoms and diagnostic 
paraclinical tests for the condition (8).
The underlying mechanisms causing this disorder 
are not well understood, however, some theories 
are suggested in the literature: dysfunctional brain-
gut interaction; corticotrophin releasing factor 
disorder; abnormal function of the autonomic 
nervous system; mitochondrial dysfunction 
due to DNA mutations that cause a deficiency 
of cellular energy production; and heightened 
hypothalamic stress response leading to nausea (1, 
2, 5, 8). Moreover, the relationship between CVS 
and migraine is suggested from a long time ago 
considering their similarities in clinical features 
and reasonable successes in treatment of CVS with 
anti-migraine medication (9, 10).
CVS attacks may cause adverse effects including 
esophagitis, hematemesis, intracellular electrolyte 
decrease, hypertension, and syndrome of 
inappropriate antidiuretic hormone secretion (4). 
This disorder can cause children to be absent at 
school, parents to be absent from work, leading 
to socio-economic losses, and incurring medical 
expenses for families (4, 7). In addition, children 
with CVS experience 5%-15% decrease in 
their quality of life (6, 7). These all indicate the 
importance of finding an effective treatment for 
CVS.
Various drugs have been experimented for this disorder. 
In children, amitriptyline, imipramine, topiramate, 
propranolol, erythromycin, cyproheptadine, and 
combination of L-Carnitine and CoQ10 have been 
What is known?
Cyclic vomiting syndrome is a chronic disease 
characterized by recurrent self-limited nausea and 
vomiting episodes with symptom-free intervals.
There is no certain treatment for cyclic vomiting 
syndrome yet.
Amitriptyline, imipramine, topiramate, propranolol, 
erythromycin, cyproheptadine, and combination of 
L-Carnitine and CoQ10 have been suggested to be 
effective in treatment of cyclic vomiting syndrome.
What is new?
Amitriptyline can be used as an effective treatment 
in children with cyclic vomiting syndrome with 
response rate of >90% in our series.
Amitriptyline has a superiority on topiramate in 
prophylactic treatment of cyclic vomiting syndrome.
Topiramate is not an effective drug for treatment of 
cyclic vomiting syndrome.
Introduction
Cyclic vomiting syndrome (CVS) is a chronic 
idiopathic disease characterized by recurrent self-
limited nausea and non-bilious vomiting episodes 
lasting from few hours to few days with symptom-
free intervals between them (1, 2). CVS is diagnosed 
based on Rome III criteria: stereotypical episodes 
of vomiting regarding onset (acute) and duration; 
three or more discrete episodes in the prior year; 
absence of nausea sensation and vomiting in 
intervals and absence of metabolic, gastrointestinal 
and central nervous system disorders (3).
CVS mostly begins in childhood and is one of 
the most important causes of reversible periodic 
nausea in children (4). It is more prevalent 
among females and its occurrence increases in 
physical and mental stresses (5-7). CVS attacks 
are characterized by severe non-bilious vomiting 
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suggested (2, 5, 6). Amitriptyline is one of the most 
common drugs with a favorable response (11). 
Moreover, topiramate is an anti-migraine medication 
(2, 12, 13) with responder rates as high as 94% (12). 
Despite these findings, there is not a reliable treatment 
protocol for CVS yet and more clinical trials need to 
be performed on this issue (5). 
In this study, we aimed to compare the efficacy of 
topiramate and amitriptyline on CVS prophylaxis.
Materials and Methods
This randomized clinical trial was conducted in 
Imam Mousa Sadr Clinic, Isfahan University 
of Medical Sciences, Isfahan, Iran and a private 
Gastroenterology Clinic from Feb 2016 to Aug 
2016. Children 3-15 yr old referred to the mentioned 
clinics with possible diagnosis of CVS were 
initially considered for participation and those with 
the following criteria were enrolled: 1) Having the 
diagnostic criteria of cyclic vomiting syndrome 
based on Rome III (3); 2) Normal neurological and 
developmental physical examination, 3) Absence 
of any metabolic disorder, 4) Absence of any 
gastrointestinal obstruction or renal impairment. 
Patients who refused to fill informed consent to 
participate in the study and those who decided 
to leave the study for reasons other than adverse 
drug reactions were excluded. Informed consent 
was obtained from patients or their parents prior 
to the study. The study was approved by regional 
Bioethics Committee of Isfahan University of 
Medical Sciences and was registered in Iranian 
Registry of Clinical Trials (registration number: 
IRCT2015102316844N2).
The diagnosis was confirmed by a Pediatric Neurologist 
or a Pediatric Gastroenterologist (coauthors of the 
study). A complete medical history was taken from 
patients and they underwent a thorough physical 
examination (including neurological examination). 
Besides, data on frequency and severity of their 
CVS attacks, history of hospitalization, and possible 
complications were collected retrospectively. 
After enrollment of patients, they were divided into 
two groups randomly using block randomization 
and each block was allocated to one of the groups 
of amitriptyline or topiramate using numbered 
envelopes thereafter. One group was treated with 
1 mg/kg/d of amitriptyline (produced by Pars Daru 
company in Iran) and the other group was treated 
with 1-2 mg/kg of topiramate (produced by Pars 
Daru company in Iran) twice a day.
Groups were followed for 3 months after starting 
the medication, looking for any response to the 
medication. They were visited regularly during 
this period every two weeks. The frequency and 
duration of attacks and adverse drug reactions were 
asked in each visit as the primary outcome of the 
study. The mean frequency and duration of attacks 
in the three months of intervention were compared 
then to the frequency and duration of attacks 
before intervention. We assumed patients who 
stopped having attacks at least in the last month 
of follow-up as vomit-free patients and compared 
them between study groups. Moreover, patients 
who had ≥50% reduction in frequency or duration 
of attacks were compared between two groups. 
During the study, patients were recommended to 
refer to clinics if they experienced any adverse 
drug reactions.
Descriptive statistics were used to describe data 
as frequencies for categorical variables and mean 
(standard deviation) for interval variables. To 
compare means, independent sample t-test, Mann-
Whitney test, and Wilcoxon signed-rank test were 
used when applicable. Chi-square test was also used 
to compare categorical data. Statistical analysis was 
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performed using SPSS 19 (Chicago, IL, USA) and a 
P-value of less than 0.05 was considered significant.
Results
Overall, 72 children were enrolled in the study 
initially and 70 of them remained as the study 
population till the end, ranging from 4 to 13 yr 
old. Patients were divided into two groups of 
36 participants initially, and 2 subjects from 
amitriptyline group decided to leave the study to 
continue treatment in another medical center. The 
mean age (yr) (standard deviation) of participants 
in the amitriptyline and topiramate group was 8.30 
(2.12) and 8.10 (2.36), respectively (P=0.705). In 
the amitriptyline group 15 (44%) subjects were 
male and in the topiramate group, 17 (47%) were 
male (P=0.794). 
Table 1 shows the disease characteristics in each 
study group before and after intervention. With 
respect to the efficacy of each drug, in amitriptyline 
group the mean monthly frequency of attacks and 
the duration of attacks both decreased significantly 
after intervention (both P-values<0.001). Same 
results were observed in topiramate group regarding 
the decline in the mean monthly frequency 
and duration of attacks after intervention (both 
P-values<0.001).
There was no statistically significant difference 
between frequency and duration of attacks in two 
groups before intervention. After intervention, 
the mean monthly frequency of attacks (SD) in 
amitriptyline and topiramate group was 0.91 (0.40) 
and 1.07 (0.55), respectively, and the difference was 
not statistically significant (P=0.368); however, 
the mean duration of attacks (SD) after drug 
administration was lower in amitriptyline group 
(3.43 (2.46) compared to 4.90 (3.03), P=0.017). 
We also compared the mean number of vomits 
per attack and the mean number of vomits per 




Median Mean ± SD1 Median Mean ± SD
Intervention Frequency of attacks2 1 1.50 ± 0.70 1 1.56± 0.66 0.603









n Frequency of attacks 1 1.07 ± 0.55 1 0.91 ± 0.40 0.368
Duration of attacks 4 4.90 ± 3.03 3 3.43 ± 2.46 0.017
Number of vomits per hour* 2 3.7 ± 3.44 2.5 2.5 ± 1.58 0.309
Number of vomits per attack** 6 6.53 ± 3.90 6 7.33 ± 3.68 0.581
1 Standard Deviation; 2 Number per month; 3 Hour per attack
* P-values are obtained from comparison of means
** Values of cases with complete remission are not reported
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hour between two study groups after intervention 
and found no statistically significant difference 
(P=0.309 and P=0.581, respectively).
Twenty-three patients (68%) in amitriptyline group 
and 14 patients (39%) in topiramate group were 
vomit-free after treatment (P=0.016). Moreover, 
27 patients (79.4%) in amitriptyline group and 
16 patients (44.4%) in topiramate group had 
≥50% improvement after intervention (P=0.003). 
Two patients in amitriptyline group experienced 
constipation during the study and 
none of the patients in topiramate group reported 
any adverse drug reactions (Table 2).
Table 2: Comparison of remission rates and side effects between two study groups
Category Topiramate (No (%)) Amitriptyline (No (%)) P-value
Complete remission
Yes 14 (38.9%) 23 (67.6%)
0.016
No 22 (61.1%) 11 (32.4%)
≥50% remission
Yes 16 (44.4%) 27 (79.4%)
0.003
No 20 (55.6%) 7 (20.6%)
Side effects Yes 0 2 (5.9%)* 0.140
* Two cases with constipation
Discussion
Amitriptyline is a tricyclic antidepressant (TCA) 
reported in previous studies (6, 14, 15) as one of 
the most effective treatments for CVS patients. 
The efficacy of this drug has been reported 52% to 
93% (6, 14, 16, 17, 18). In contrast to amitriptyline, 
topiramate is studied in fewer studies before 
and only small number of reports are available 
suggesting topiramate as an appropriate and 
effective choices for prophylactic treatment of 
CVS (6, 12, 13).
In the present study, patients showed a favorable 
response to both amitriptyline and topiramate 
regarding decrease in frequency and duration of 
attacks. We observed 39% full remission after 
topiramate administration and 68% full remission 
after amitriptyline administration. Andersen et al 
reported 73% of patients with complete remission 
and 18% with partial remission after a follow-up 
of 5 months to 10 yr (19). Moreover, in a study, 
93% of their patients experienced decreased 
symptoms and 26% stopped having attacks after 
3 months of treatment with amitriptyline (17). 
In a randomized clinical trial conducted by our 
group, we found full remission among 65.6% of 
patients receiving amitriptyline after 6 months of 
follow-up (18). Additionally, a prospective Iranian 
study on children with CVS reported effectiveness 
of amitriptyline in 56% of their patients (20). 
Our findings on efficacy of amitriptyline seem 
to be consistent with these reports although they 
had different settings, methods, and follow-up 
42 Iran J Child Neurol. Winter 2019 Vol. 13 No. 1
Comparison of the Efficacy of Amitriptyline and Topiramate in Prophylaxis... 
durations.
On the other hand, there are very limited data 
available on the efficacy of topiramate on CVS 
prophylaxis. Boles et al. administered topiramate 
for two patients with refractory attacks while 
being treated with other drugs and they both had 
resolution of attacks (2). Moreover, another study 
showed about 15% complete remission and 45% 
partial remission in 18 patients being treated 
with topiramate (13). A recent retrospective 
study evaluated 16 pediatric patients treated with 
topiramate for at least 12 months and reported 
freedom of attacks in 81% of them and >50% 
decrease of attacks in 13% of them (12). Although 
we had decreased frequency and duration of attacks 
in patients treated with topiramate, only 39% of 
our cases stopped having attacks. However, this is 
hard to compare our findings with previous ones 
considering the short follow up of our cases and 
retrospective design of previous studies.
There are no previous studies comparing the 
efficacy of topiramate and amitriptyline on 
prophylactic therapy of CVS, however, a recent 
meta-analysis on migraine medications showed 
that amitriptyline was weakly superior to other 
drugs including topiramate (21). Although the 
relationship between CVS and migraine has been 
suggested since long time ago (9), these findings 
may not be applicable for patients with diagnosis 
of CVS. In this study, we observed a more 
favorable response to amitriptyline compared to 
topiramate. The duration of attacks was decreased 
more in amitriptyline group and more patients 
stopped having attacks in amitriptyline group 
either. Therefore, we suggest the superiority of 
amitriptyline on topiramate in prophylactic therapy 
of CVS.
This study had some limitations: first, considering 
the design and methodology of the study we were 
able to enroll limited number of patients which 
may affect our results. Second, we did not evaluate 
various doses of drugs in the patients and a single 
dose was only administered. Third, we evaluated 
patients after three months of therapy which 
is a short follow up period compared to most 
previous studies and administered drugs may have 
different long-term therapeutic effects. Therefore, 
we believe a different outcome may be observed 
in similar studies with longer follow up periods. 
Fourth, we collected data considering frequency 
and duration of attacks before intervention based on 
patients’ medical history and parents’ declaration. 
Therefore, a recall bias may have affected our 
results and overestimated data regarding attack 
characteristics before intervention. Fifth, we 
visited patients regularly after intervention caused 
a placebo effect and thus a better overall outcome 
in both groups. Despite these limitations, this is 
the first clinical trial comparing the efficacy of 
topiramate and amitriptyline in children with CVS.
In conclusion, amitriptyline is a better choice 
to reduce severity of CVS attacks compared to 
topiramate, in a short-term evaluation. Studies 
with longer follow-up are required to investigate 
these findings in a longer period. There is still lack 
of evidence on this issue, especially clinical trials, 
and further studies are recommended to confirm 
our findings.
Acknowledgement
We want to thank Vice-Chancellor for Research 
and Technology of Isfahan University of Medical 
Sciences for funding this project (grant number: 
393229). Moreover, we need to thank Dr. Marjan 
Mansourian for her great help in statistical analysis 
of data.
43Iran J Child Neurol. Winter 2019 Vol. 13 No. 1
Comparison of the Efficacy of Amitriptyline and Topiramate in Prophylaxis... 
Clinical trial registration
The study was registered in Iranian Registry of 
Clinical Trials (www.IRCT.ir) with registration 
number: IRCT2015102316844N2
Authors’ Contribution
Yaghini and Saneian had the main idea of the 
project, designed the study, cooperated in study 
implementation and data collection, interpreted 
the data, critically reviewed the manuscript, and 
approved the final manuscript as submitted. 
Bagherian and Badihian helped in designing, 
cooperated in implementation and data collection, 
analyzed and interpreted the data, prepared the 
first draft of the manuscript, and approved the final 
manuscript as submitted.
Conflict of interest
None of the authors declare any conflict of interest.
References
1. Ölmez A, Köse G, Turanli G. Cyclic vomit-
ing with generalized epileptiform discharges re-
sponsive to topiramate therapy. Pediatr Neurol 
2006;35(5):348-51.
2. Boles RG. High degree of efficacy in the treat-
ment of cyclic vomiting syndrome with combined 
co-enzyme Q10, L-carnitine and amitriptyline, a 
case series. BMC Neurol 2011;11(1):102.
3. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes 
E, Hyams JS, Staiano A, et al. Childhood func-
tional gastrointestinal disorders: child/adolescent. 
Gastroenterology 2006;130(5):1527-37.
4. Fleisher DR, Matar M. The cyclic vomiting syn-
drome: a report of 71 cases and literature review. 
J Pediatr Gastroenterol Nutr 1993;17(4):361-9.
5. Li BU, Lefevre F, Chelimsky GG, Boles RG, 
Nelson SP, Lewis DW, et al. North American So-
ciety for Pediatric Gastroenterology, Hepatology, 
and Nutrition consensus statement on the diagno-
sis and management of cyclic vomiting syndrome. 
J Pediatr Gastroenterol Nutr 2008;47(3):379-93.
6. Boles RG, Lovett-Barr MR, Preston A, Li BU, 
Adams K. Treatment of cyclic vomiting syn-
drome with co-enzyme Q10 and amitriptyline, a 
retrospective study. BMC Neurol 2010; 10:10 .
7. Fleisher DR. The cyclic vomiting syndrome de-
scribed. J Pediatr Gastroenterol Nutr 1995;21:S1-
S5.
8. Venkatesan T, Tarbell S, Adams K, McKanry 
J, Barribeau T, Beckmann K, et al. A survey of 
emergency department use in patients with cy-
clic vomiting syndrome. BMC Emerg Med 2010; 
10:4.
9. Li B, Murray RD, Heitlinger LA, Robbins JL, 
Hayes JR. Is cyclic vomiting syndrome related to 
migraine? J Pediatr 1999;134(5):567-72.
10. Yaghini, O., N. Badihian, and S. Badihian, 
The Efficacy of Topiramate in Benign Paroxys-
mal Torticollis of Infancy: Report of Four Cases. 
Pediatrics 2016;137(4):p. e20150868.
11. Moses J, Keilman A, Worley S, Radhakrishnan 
K, Rothner AD, Parikh S. Approach to the diag-
nosis and treatment of cyclic vomiting syndrome: 
a large single-center experience with 106 patients. 
Pediatr Neurol 2014;50(6):569-73.
12. Sezer OB, Sezer T. A new approach to the 
prophylaxis of cyclic vomiting: Topiramate. J 
Neurogastroenterol Motil 2016; 22(4):656-660.
13. Kumar N, Bashar Q, Reddy N, Sengupta J, 
Ananthakrishnan A, Schroeder A, et al. Cyclic 
Vomiting Syndrome (CVS): is there a difference 
based on onset of symptoms-pediatric versus 
adult? BMC Gastroenterol 2012;12:52.
14. Boles RG, Powers AL, Adams K. Cy-
clic vomiting syndrome plus. J Child Neurol 
44 Iran J Child Neurol. Winter 2019 Vol. 13 No. 1
Comparison of the Efficacy of Amitriptyline and Topiramate in Prophylaxis... 
2006;21(3):182-9.
15. Hejazi RA, Reddymasu SC, Namin F, Laven-
barg T, Foran P, McCallum RW. Efficacy of tricy-
clic antidepressant therapy in adults with cyclic 
vomiting syndrome: a two-year follow-up study. 
J Clin Gastroenterol 2010;44(1):18-21.
16. Lee LY, Abbott L, Mahlangu B, Moodie SJ, 
Anderson S. The management of cyclic vomiting 
syndrome: a systematic review. Eur J Gastroen-
terol Hepatol 2012;24(9):1001-6.
17. Namin F, Patel J, Lin Z, Sarosiek I, Foran P, 
Esmaeili P, et al. Clinical, psychiatric and man-
ometric profile of cyclic vomiting syndrome in 
adults and response to tricyclic therapy1. Neuro-
gastroenterol Motil 2007;19(3):196-202.
18. Badihian N, Saneian H, Badihian S, Yaghini 
O. Prophylactic therapy of cyclic vomiting syn-
drome in children: comparison of amitriptyline 
and cyproheptadine: a randomized clinical trial. 
Am J Gastroenterol 2018 Jan;113(1):135-140.
19. Andersen JM, Sugerman KS, Lockhart JR, 
Weinberg WA. Effective prophylactic therapy 
for cyclic vomiting syndrome in children us-
ing amitriptyline or cyproheptadine. Pediatrics 
1997;100(6):977-81.
20. Haghighat M, Rafie SM, Dehghani SM, Falla-
hi GH, Nejabat M. Cyclic vomiting syndrome in 
children: experience with 181 cases from southern 
Iran. World J Gastroenterol 2007;13(12):1833-6.
21. Jackson JL, Cogbill E, Santana-Davila R, 
Eldredge C, Collier W, Gradall A, et al. A com-
parative effectiveness meta-analysis of drugs for 
the prophylaxis of migraine headache. PloS One 
2015;10(7):e0130733.
